Isorhamnetin Protects against Doxorubicin-Induced Cardiotoxicity In Vivo and In Vitro

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Sun, Jing ^a   Sun, Guibo ^a   Meng, Xiangbao ^a   Wang, Hongwei ^b   Luo, Yun ^a   Qin, Meng ^a   Ma, Bo ^a   Wang, Min ^a   Cai, Dayong ^a   Guo, Peng ^a   Sun, Xiaobo ^a  

^a INSTITUTE OF MEDICINAL PLANT DEVELOPMENT   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CASPASE 3; CASPASE 9; CATALASE; CREATINE KINASE; CYTOCHROME C; DOXORUBICIN; GLUTATHIONE PEROXIDASE; ISORHAMNETIN; LACTATE DEHYDROGENASE; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; SUPEROXIDE DISMUTASE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BODY WEIGHT; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CELL PROTECTION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HEART INDEX; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART PROTECTION; HEART VACUOLATION; HEART WEIGHT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CELL DEATH; CELL LINE; CELL SURVIVAL; DOXORUBICIN; HEART DISEASES; INTRACELLULAR SPACE; L-LACTATE DEHYDROGENASE; MALE; MAP KINASE SIGNALING SYSTEM; MITOCHONDRIA; MYOCARDIUM; MYOCYTES, CARDIAC; PROTECTIVE AGENTS; PROTO-ONCOGENE PROTEINS C-BCL-2; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; TUMOR SUPPRESSOR PROTEIN P53;

RATTUS;

EID: 84878420599     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0064526     Document Type: Article

References (48)

1. Takemura G, Fujiwara H, (2007) Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49: 330-352.
2. Chang WT, Li J, Haung HH, Liu H, Han M, et al. (2011) Baicalein protects against doxorubicin-induced cardiotoxicity by attenuation of mitochondrial oxidant injury and JNK activation. J Cell Biochem 112: 2873-2881.
3. Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC, (2010) Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis 53: 105-113.
4. Scott JM, Khakoo A, Mackey JR, Haykowsky MJ, Douglas PS, et al. (2011) Modulation of anthracycline-induced cardiotoxicity by aerobic exercise in breast cancer: current evidence and underlying mechanisms. Circulation 124: 642-650.
5. van Dalen EC, Caron HN, Dickinson HO, Kremer LC, (2011) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 15: CD003917.
6. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, et al. (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52: 1213-1225.
7. Zhang YW, Shi J, Li YJ, Wei L, (2009) Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 57: 435-445.
8. Xiao J, Sun GB, Sun B, Wu Y, He L, et al. (2012) Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. Toxicology 292: 53-62.
9. Huang J, Yang J, Maity B, Mayuzumi D, Fisher RA, (2011) Regulator of G protein signaling 6 mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. Cancer Res 71: 6310-6319.
10. Liu J, Mao W, Ding B, Liang CS, (2008) ERKs/p53 signal transduction pathway is involved in doxorubicin-induced apoptosis in H9c2 cells and cardiomyocytes. Am J Physiol Heart Circ Physiol 295: H1956-1965.
11. Circu ML, Aw TY, (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48: 749-762.
12. Florentin A, Arama E, (2012) Caspase levels and execution efficiencies determine the apoptotic potential of the cell. J Cell Biol 196: 513-527.
13. Choi HJ, Kang KS, Fukui M, Zhu BT, (2011) Critical role of the JNK-p53-GADD45alpha apoptotic cascade in mediating oxidative cytotoxicity in hippocampal neurons. Br J Pharmacol 162: 175-192.
14. Qin Q, Liao G, Baudry M, Bi X, (2010) Cholesterol Perturbation in Mice Results in p53 Degradation and Axonal Pathology through p38 MAPK and Mdm2 Activation. PLoS One 5: e9999.
15. Banu SK, Stanley JA, Lee J, Stephen SD, Arosh JA, et al. (2011) Hexavalent chromium-induced apoptosis of granulosa cells involves selective sub-cellular translocation of Bcl-2 members, ERK1/2 and p53. Toxicol Appl Pharmacol 251: 253-266.
16. Kang YJ, Zhou ZX, Wang GW, Buridi A, Klein JB, (2000) Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem 275: 13690-13698.
17. Zhao G, Duan J, Xie Y, Lin G, Luo H, et al. (2012) Effects of solid dispersion and self-emulsifying formulations on the solubility, dissolution, permeability and pharmacokinetics of isorhamnetin, quercetin and kaempferol in total flavones of Hippophae rhamnoides L. Drug Dev Ind Pharm. 3: 3.
18. Panda VS, N SR, (2009) Evaluation of cardioprotective activity of Ginkgo biloba and Ocimum sanctum in rodents. Altern Med Rev 14: 161-171.
19. Bao M, Lou Y, (2006) Isorhamnetin prevent endothelial cell injuries from oxidized LDL via activation of p38MAPK. Eur J Pharmacol 547: 22-30.
20. Ibarra M, Moreno L, Vera R, Cogolludo A, Duarte J, et al. (2003) Effects of the flavonoid quercetin and its methylated metabolite isorhamnetin in isolated arteries from spontaneously hypertensive rats. Planta Med 69: 995-1000.
21. Zhang N, Pei F, Wei H, Zhang T, Yang C, et al. (2011) Isorhamnetin protects rat ventricular myocytes from ischemia and reperfusion injury. Exp Toxicol Pathol 63: 33-38.
22. Sun B, Sun GB, Xiao J, Chen RC, Wang X, et al. (2012) Isorhamnetin inhibits H(2)O(2)-induced activation of the intrinsic apoptotic pathway in H9c2 cardiomyocytes through scavenging reactive oxygen species and ERK inactivation. J Cell Biochem 113: 473-485.
23. Lee HJ, Lee EO, Ko SG, Bae HS, Kim CH, et al. (2008) Mitochondria-cytochrome C-caspase-9 cascade mediates isorhamnetin-induced apoptosis. Cancer Lett 270: 342-353.
24. Kim JE, Lee DE, Lee KW, Son JE, Seo SK, et al. (2011) Isorhamnetin suppresses skin cancer through direct inhibition of MEK1 and PI3-K. Cancer Prev Res (Phila) 4: 582-591.
25. Jahnukainen K, Jahnukainen T, Salmi TT, Svechnikov K, Eksborg S, et al. (2001) Amifostine protects against early but not late toxic effects of doxorubicin in infant rats. Cancer Res 61: 6423-6427.
26. Liu Q, Kou JP, Yu BY, (2011) Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-kappaB activation. Neurochem Int 58: 119-125.
27. Swamy AV, Gulliaya S, Thippeswamy A, Koti BC, Manjula DV, (2012) Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol 44: 73-77.
28. Pengfei L, Tiansheng D, Xianglin H, Jianguo W, (2009) Antioxidant properties of isolated isorhamnetin from the sea buckthorn marc. Plant Foods Hum Nutr 64: 141-145.
29. Ramachandran L, Manu KA, Shanmugam MK, Li F, Siveen KS, et al. (2012) Isorhamnetin inhibits proliferation and invasion and induces apoptosis through the modulation of peroxisome proliferator-activated receptor gamma activation pathway in gastric cancer. J Biol Chem 287: 38028-38040.
30. Tikoo K, Sane MS, Gupta C, (2011) Tannic acid ameliorates doxorubicin-induced cardiotoxicity and potentiates its anti-cancer activity: potential role of tannins in cancer chemotherapy. Toxicol Appl Pharmacol 251: 191-200.
31. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
32. Li L, Pan Q, Han W, Liu Z, Hu X, (2007) Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling. Clin Cancer Res 13: 6753-6760.
33. Xu Y, Liu Z, Sun J, Pan Q, Sun F, et al. (2011) Schisandrin B prevents doxorubicin-induced chronic cardiotoxicity and enhances its anticancer activity in vivo. PLoS One 6: e28335.
34. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, et al. (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48: 2258-2262.
35. Kalyanaraman B, Joseph J, Kalivendi S, Wang S, Konorev E, et al. (2002) Doxorubicin-induced apoptosis: implications in cardiotoxicity. Mol Cell Biochem 234-235: 119-124.
36. Pryor WA, Houk KN, Foote CS, Fukuto JM, Ignarro LJ, et al. (2006) Free radical biology and medicine: it's a gas, man! Am J Physiol Regul Integr Comp Physiol. 291: R491-511.
37. Green PS, Leeuwenburgh C, (2002) Mitochondrial dysfunction is an early indicator of doxorubicin-induced apoptosis. Biochim Biophys Acta 1588: 94-101.
38. Yoshida M, Shiojima I, Ikeda H, Komuro I, (2009) Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity. J Mol Cell Cardiol 47: 698-705.
39. Cory S, Adams JM, (2002) The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656.
40. Wang Z, Zheng M, Li Z, Li R, Jia L, et al. (2009) Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. Cancer Res 69: 6556-6564.
41. Thandavarayan RA, Watanabe K, Sari FR, Ma M, Lakshmanan AP, et al. (2010) Modulation of doxorubicin-induced cardiac dysfunction in dominant-negative p38alpha mitogen-activated protein kinase mice. Free Radic Biol Med 49: 1422-1431.
42. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284.
43. Baines CP, Molkentin JD, (2005) STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 38: 47-62.
44. Martin MA, Serrano AB, Ramos S, Pulido MI, Bravo L, et al. (2010) Cocoa flavonoids up-regulate antioxidant enzyme activity via the ERK1/2 pathway to protect against oxidative stress-induced apoptosis in HepG2 cells. J Nutr Biochem 21: 196-205.
45. Brantley-Finley C, Lyle CS, Du L, Goodwin ME, Hall T, et al. (2003) The JNK, ERK and p53 pathways play distinct roles in apoptosis mediated by the antitumor agents vinblastine, doxorubicin, and etoposide. Biochem Pharmacol 66: 459-469.
46. Kulich SM, Chu CT, (2003) Role of reactive oxygen species in extracellular signal-regulated protein kinase phosphorylation and 6-hydroxydopamine cytotoxicity. J Biosci 28: 83-89.
47. Stadheim TA, Xiao H, Eastman A, (2001) Inhibition of extracellular signal-regulated kinase (ERK) mediates cell cycle phase independent apoptosis in vinblastine-treated ML-1 cells. Cancer Res 61: 1533-1540.
48. Wang H, Yu P, Gou H, Zhang J, Zhu M, et al. (2012) Cardioprotective Effects of 20(S)-Ginsenoside Rh2 against Doxorubicin-Induced Cardiotoxicity In Vitro and In Vivo. Evid Based Complement Alternat Med 2012: 506214.